The role of adrenal androgens as drivers for castration-resistant prostate cancer (CRPC) growth in man is generally accepted; however, the value of preclinical mouse models of CRPC is debatable, since mouse adrenals do not produce steroids activating the androgen receptor. In this study, we confirmed the expression of enzymes essential for de novo synthesis of androgens in mouse adrenals, with high intratissue concentration of progesterone (P 4 ), and moderate levels of androgens, such as androstenedione, testosterone, and dihydrotestosterone in the adrenal glands of both intact and orchectomized (ORX) mice. ORX alone had no effect on serum P 4 concentration, whereas orchectomized and adrenalectomized (ORX+ADX) resulted into a significant decrease in serum P 4 , and into a further reduction in the low levels of serum androgens (androstenedione, testosterone, and dihydrotestosterone), measured by mass spectrometry. In line with this, the serum PSA and growth of VCaP xenografts in mice after ORX+ADX was markedly reduced compared to ORX alone, and the growth difference was not abolished by a glucocorticoid treatment. Moreover, ORX+ADX altered the androgen-dependent gene expression in the tumors similar to that recently shown for the enzalutamide treatment. These data indicate that that in contrast to the current view, and similar to human, mouse adrenals synthesize significant amounts of steroids that contribute to the androgen receptor-dependent growth of CRPC.
INTRODUCTION
Prostate cancer (PCa) is the second most common cancer and fifth leading cause of death from cancer in men worldwide 1 . At early stages of PCa, when the cancer is clinically localized, the disease is curable with surgery or radiation, whereas systemic therapies are needed for the management of advanced disease. Androgens, acting via the androgen receptor (AR) are essential for PCa growth 2 . Accordingly, androgen deprivation therapy (ADT), achieved by suppression of gonadal androgen synthesis via orchectomy (ORX) or chemically with gonadotropin-releasing hormone (GnRH) analogs, has been the first-line treatment of advanced and metastatic prostate cancer over 70 years. Although the initial response to these treatments is nearly complete, the majority of patients become resistant to ADT, developing a lethal castration-resistant prostate cancer (CRPC) 3 . In most cases, the CRPC growth involves reactivation of the AR signaling. This concept has been clinically proven with two recently approved treatments for CRPC. These include a non-steroidal AR antagonist (enzalutamide) that also inhibit the nuclear translocation of AR 4 , and a selective CYP17A1 inhibitor (abiraterone acetate) blocking the critical step in androgen biosynthesis [5] [6] [7] . Also several other new treatments targeting directly the AR signaling pathway are under development 8, 9 . Despite improved response ratios and overall survival with the new treatments, current therapies are not curative 8, 10 .
It is known that therapies leading to suppression of androgen action may lead to the development of AR pathway-related resistance mechanisms, including AR gene amplification 11 or overexpression 12 , production of mutated forms of AR 13, 14 or AR splice variants 15, 16 , and the induction of intratumoral androgen biosynthesis 17, 18 . Approximately 90% to 95% of circulating androgens in men are expected to be produced in testis and the remaining 5% to 10% in the adrenal cortex 19 .
Under ADT, normal and cancerous prostate tissue have shown to utilize adrenal-derived DHEA for M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 4 the local synthesis of T and dihydrotestosterone (DHT) 20, 21 . However, the significance of adrenal androgens in the development of CRPC has been difficult to establish. Results have also shown that certain PCa cell lines (PC346 and VCaP) predominantly exploit adrenal precursors for androgen production, whereas others (LNCaP) utilize equally well both adrenal precursors and de novo synthesis 17, 21, 22 . On the other hand, in clinical CRPC specimens, only low intratumoral levels of enzymes of the first steps of steroid synthesis have been observed, but an up-regulation of enzymes essential for conversion of adrenal precursors to active androgens were reported, suggesting a central role for the adrenal precursors in androgen production 20, 23 . Furthermore, the mutated AR (T878A) expressed, eg. in LNCaP cells, is also activated by the precursors of androgen production, including progesterone 24, 25 .
In contrast to human, murine adrenals do not produce large quantities of DHEA or its sulphate (DHEA-S), partially due to the low levels of CYP17A1 26 , and thus, the value of preclinical mouse models for studying androgen-dependency of CRPC has been questioned. In the present study, VCaP xenografts were used to study the role of murine adrenal steroids in CRPC growth. VCaP cells, originally established from a vertebral bone metastasis of a patient with CRPC 27 , express wild type AR 27 , and the VCaP xenografts in ORX mice demonstrate key characteristics of clinical CRPC, including up-regulation of intratumoral androgen biosynthesis, aberrant expression of both full-length AR and various AR splice variants, and responsiveness to AR antagonists 28, 29 . The results show that ADX attenuates VCaP tumor growth in ORX mice, and results in reduction of intratumoral DHT, as well as down-regulation of androgen-dependent genes. Our data indicate that the steroid synthesis machinery in the mouse adrenal cortex contributes to the androgen-dependent growth of VCaP xenografts in castrated mice.
VCaP xenograft growth in intact, orchectomized, and both orchectomized and adrenalectomized mice
Development and growth of the VCaP tumors was monitored by measuring the tumor volume twice a week, and by detecting the serum concentration of prostate specific antigen (PSA) every 10 days.
The volume of the tumors was calculated according to following formula: W 2 * L / 2 (W = shorter diameter, L = longer diameter of the tumor).
For PSA analysis, blood was collected from saphenous vein, and the PSA was measured with a time-resolved fluorometer (Wallac, PerkinElmer Analytical Life Sciences, Turku, Finland) as described previously 30 . Kim Pettersson (University of Turku, Finland) kindly provided reagents for the PSA assay.
Tumors were grown for seven weeks, until the mean volume of the tumors reached approximately 300 mm 3 (range 51 to 691 mm 3 ), and the mean serum PSA value was approximately 20 µg/L (range 1 to 93 µg/L). The experimental groups: intact (n=15), orchectomized (ORX; n=14), and both
VCaP xenograft growth in both orchectomized and adrenalectomized mice with corticosterone treatment
The VCaP tumors were initially established as described above in intact mice. When the tumors reached approximately 300 mm 3 (range 46-610 mm 3 ) the mice were allocated into three groups: ORX (n=13), ORX+ADX (n=13), and ORX+ADX with corticosterone treatment (n=13). ORX and ADX interventions were performed as described above, and after operations, corticosterone (Sigma-Aldrich, St.Louis, MO) was provided orally for four weeks (3 mg/kg/day) until the end of the study.
The dose of corticosterone was selected based on literature 32 The quality of the sequenced reads was checked using FastQC tool. STAR v2.5.0c 34 was used to align the reads to the mouse reference genome mm10, available at UCSC (Illumina iGenomes web site, San Diego, CA). The number of uniquely mapped reads associated with each gene according to RefSeq gene annotation was counted using the subread v1.5.0 R-package 35 . The RNA-seq data are available from the Gene Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/; accession number GSE117771). The downstream analysis of the data was performed using R version 3.2.2 36 and its corresponding Bioconductor module 3.2 37 . The count data were normalized for library size using the Trimmed Mean of M-values (TMM) method implemented in the edgeR Rpackage 38 . The normalized data were further transformed using the voom approach in the limma R- 39 . R package ROTS 40 was used for performing the statistical testing and false discovery rate (FDR) < 0.05 and absolute fold change > 2 was required for detecting the differentially expressed genes between the intact and ORX groups. The hierarchical clustering of the scaled normalized expression values of differentially expressed AR-regulated genes was performed using Euclidean distance and Ward's method, implemented in the R package pheatmap 41 .
Immunoblotting
Tumor and adrenal gland samples were homogenized using a TissueLyzer LT and stainless steel beads (Qiagen, Hilden, Germany) in RIPA-lysis buffer containing the following: 150 mmol/l Tris-HCl, 1 % NP-40, 0.5 % sodium deoxycholate, 1 mmol/L EDTA, 1 mmol/L SDS, 100 mmol/L sodium orthovanadate (Sigma-Aldrich, St.Louis, MO), and cOmplete Mini protease inhibitor (Roche Diagnostics, Mannheim, Germany). AR was immunoblotted with standard techniques, as previously shown 28 . ImageJ software version 1.51K (NIH, Bethesda, MD) was used to compare and quantify the intensity of bands on scanned images of membranes.
Statistical analysis
The statistical tests were chosen depending on the results of the preliminary Shapiro-Wilk tests of data normality. Non-parametric Mann-Whitney, Kruskal-Wallis, and Dunn's multiple comparison tests were applied in RT-qPCR comparisons on single gene level, and to test the differences in the steroid concentrations in intact, ORX, and ORX+ADX mice, in comparison to vehicle and corticosterone-treated animals. Correlation of Cyp17a1 and Lhcgr mRNA expression in adrenal gland was calculated using Spearman correlation coefficient. These univariate statistical analyses were performed using GraphPad Prism 7 software (GraphPad Software, San Diego, CA). The longitudinal analysis of PSA profiles between the interventions was performed using mixed-effects models that infer differences in population growth slope co-efficients over the whole time period of M A N U S C R I P T
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10 the intervention 42 , where the individual prognostic baseline variables were accounted for by incorporating them in the baseline animal matching 31 . The R statistical software (version 3.2.1) 36 together with the preclinical analysis R-package hamlet (version 0.9.5) were utilized in the longitudinal analyses 31 . P-value < 0.05 was considered statistically significant.
RESULTS

Growth of castration-resistant VCaP tumors is partially adrenal driven
Orthotopic VCaP xenografts in ORX hosts display the fundamental properties of CRPC, namely androgen-dependent growth and secretion of PSA, as well as AR overexpression and up-regulation of full-length AR and its splice variants 28 . In the present study, similar growth properties were confirmed for subcutaneous VCaP xenografts. As expected, ORX and ORX+ADX caused a transient repression of tumor growth rate and serum PSA concentrations ( Fig. 1A, B ). Notably, ADX delayed the relapse and reduced tumor growth in ORX mice. At the end of the study the tumor volumes in the ORX+ADX mice were smaller (P < 0.001) than those in the ORX group ( Fig.1A) . Similar pattern was observed in serum PSA concentrations ( Fig. 1A) . One week post ORX, PSA concentration reduced 6-fold, (from 20 µg/L to 3.4 µg/L), whereas 22-fold decline (from 20 µg/L to 0.9 µg/L) was seen in ORX+ADX mice. In the ORX group, serum PSA reached the pre-castration levels at about seven weeks, but in ORX+ADX group the increase in PSA levels was less evident and did not reach the pre-castration levels within the nine week-long study period ( Fig. 1B) . At the end of the study, PSA concentration in ORX+ADX mice was significantly (P < 0.05) lower compared to ORX mice Thus, these data show that ADX significantly reduces the growth of the castration-resistant VCaP tumors, indicating a contribution of adrenals to the CRPC xenograft growth in mice.
The possible role of glucocorticoids in ADX response was next studied. Corticosterone replacement at physiological dose had no effect on the growth of VCaP xenografts in ORX+ADX mice (Fig.   1C ). ORX, however, significantly (P < 0.01) increased the weights of adrenals (Fig. 1D ), and as expected, ORX+ADX resulted into a marked increase in serum ACTH-level (26-fold higher compared to ORX), whereas a smaller change (7-fold compared to ORX, Fig. 1E ) was observed in corticosterone-treated mice. These data confirm that the inhibition of VCaP xenograft growth by ADX is not due to the lack of adrenal glucocorticoids.
Mouse adrenals express enzymes involved in androgen production
Since the lack of glucocorticoids did not explain the inhibition of VCaP xenograft growth in ORX+ADX group, the expression of adrenal enzymes involved in sex steroid biosynthesis was analyzed by RNA-seq and RT-qPCR analysis ( Fig. 2A, B , and D). Interestingly, RNA-seq revealed mRNA expression of 59 CYP, 16 AKR, and 62 SDR family enzymes. These include both classical steroid biosynthesizing enzymes, as well as several other enzymes whose role in steroid synthesis is yet to be defined, suggesting various possible pathways for androgen production. Some of these enzymes are known to be involved in early stages of steroid synthesis and, thus, affect both glucocorticoid and androgen production, whereas some are more specifically related to androgen production. Of these, the mRNA expression of Akr1c6 (homolog for human AKR1C4), Akr1c18, Akr1d1, Cyp17a1, Ugt1a1, Cyp11a1, Hsd3b1, Hsd3b2, Srd5a1, and Srd5a3 were confirmed by RT-qPCR and were shown to be induced 1.6 to 3736.6-fold by ORX (P < 0.01 to 0.001), with highest induction in the expression of Akr1c18 ( Fig. 2A, B ). Furthermore, ORX resulted in marked up- Fig. 2E ), suggesting that high circulating luteinizing hormone (LH) induces the early steps of the adrenal steroidogenesis in ORX mice. Top 30 up-regulated and downregulated genes in the RNA-seq data in mouse adrenal gland are shown in Supplementary Table S1 .
Mouse adrenals produce active androgens and their precursors, and contribute to sex steroid production in VCaP xenografts in castrated mice
The enzymatic machinery in adrenal glands, possibly involved in the androgen biosynthesis, prompted us to analyze the intra-adrenal steroid concentrations of intact and ORX male mice. Our data showed that, together with P 4 , high concentrations (>1 ng/g tissue) of all main classical androgens (A-dione, T, and DHT) were present in the adrenals of intact mice. The mean concentrations of P 4 , A-dione, T, and DHT were 4,367, 1.7, 3.0, and 1.5 ng/g, respectively (Fig.   3A ). Thus, the P 4 concentration was over 1,000-fold higher than any of the quantitated androgens.
In addition, high tissue-serum ratios for A-dione (84:1), DHT (94:1), and P 4 (50000:1) indicate local synthesis of these steroids in the adrenal glands ( Fig. 3B ). Interestingly, ORX had no effect on intra-adrenal A-dione, T, DHT, or P 4 concentrations. However, the adrenal-serum ratio of all these steroids increased significantly after ORX (Fig. 3B ). These findings further support the hypothesis of intra-adrenal production of androgens in mice.
Notably, ORX alone had no effect on serum or intratumoral P 4 concentrations (Fig. 4A, B) , whereas ORX+ADX resulted into 13-fold and 21-fold reduction in the P 4 concentration in the serum (Fig.   4A ) and in the tumor (Fig. 4B) , respectively. This observation confirms that both serum and intratumoral P 4 mainly originates from the adrenals. ADX further reduced T and DHT concentrations in the serum of ORX mice (Fig. 4A ), suggesting that murine adrenals indeed contribute to circulating androgen concentrations.
In line with our previous data 28 , intratumoral P 4 and the androgen concentrations remained high in the castration-resistant VCaP tumors, despite the low serum steroid concentrations in ORX mice ( Fig. 4B) . Importantly, ADX decreased intratumoral A-dione, T, DHT, and P 4 concentrations in ORX mice (Fig. 4B ). However, intratumoral synthesis of DHT is maintained after ADX, as tumorserum ratio of DHT remains high. Taken together, the present data show the role of adrenals in the regulation of intratumoral androgen concentration in the VCaP xenografts in ORX mice.
Adrenalectomy affects androgen-dependent gene expression in the CRPC VCaP tumors
In line with our published data 28 , the present study confirmed the up-regulation of mRNAs for fulllength AR and AR splice variants by ORX ( Fig. 5A) . Interestingly, ADX further contributed to the over expression of AR in castration-resistant VCaP xenografts (Fig. 5A) . At the protein level, however, no induction by ADX was observed (Fig. 5B) , likely due to lower stability of the protein in the presence of only a low amount of the ligand 43, 44 . ADX+ORX also induced the expression of certain enzymes involved in DHT synthesis in the tumors, including AKR1C3 and SDR5A1 (Fig.   5C ). In addition, the expression of set of genes previously 29 identified to be regulated by antiandrogens in castration-resistant VCaP xenografts was analyzed. Of these genes, SYLT2 and NOV were up-regulated and FKBP5 and ST6GAlNAcl down-regulated after ADX+ORX (Fig. 5D ).
Overall, the effect of ADX in castration-resistant VCaP xenografts was similar to that shown for antiandrogens (enzalutamide and apalutamide) 29
DISCUSSION
Xenograft models generated using PCa cells and clinical tissue specimens are widely used [45] [46] [47] for studying PCa biology and drug responses. The relevance of mouse CRPC models has, however,
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14 been questioned due to species differences in extragonadal sex steroid production 17, 48 . In humans, weak androgens DHEA and DHEA-S, produced by adrenal glands, are recognized as precursors for the intratumoral synthesis of T and DHT 49 . In contrast, production of DHEA and DHEA-S by murine adrenals has been considered negligible, and, thus, having no significant contribution to local androgen biosynthesis in CRPC xenografts 26 . In the present study, this view was challenged by using up-to-date steroid profiling methodology, and evidence was provided for the significance of murine adrenal steroids in the regulation of CRPC xenograft growth.
VCaP xenografts in ORX mice exhibit several of the key characteristics of clinical CRPC, including castration-resistant growth, intratumoral androgen biosynthesis, marked expression of both fulllength AR and various AR splice variants, and responsiveness to AR antagonists 28, 29 . The role of adrenal steroids has not been addressed in the previous VCaP xenograft studies, possibly due to the presumption that murine adrenals lack the enzymatic machinery needed for the production of The present study demonstrates that mouse adrenals produce biologically significant amounts of T and DHT, and contribute to the circulating levels of these androgens, especially after ORX. RT-qPCR analyses were in line with the steroid measurements, showing that murine adrenals express some of the key enzymes that selectively contribute to androgen synthesis (Hsd17b3, Akr1c6, and Hsd17b6) 48 . The discrepancy between previous studies 26 and our current results regarding murine adrenal androgen production may, at least partly, be explained by methodological issues. A highly sensitive mass spectrometry-based method was used to measure the intratissue and serum steroid concentrations 33 , as against the less sensitive assays used in the previous studies. In line with earlier data 48 , it was also observed that ORX caused a marked induction in the expression of adrenal LH receptor (Lhcgr) expression. Interestingly, a strong correlation was observed between the expression of Lhcgr and Cyp17a1, encoding for a key enzyme necessary for the synthesis of all steroid hormones in the adrenal cortex. As ORX increases circulating LH levels 51 , these data suggest an auto-regulatory loop for LH to promote the early steps of steroidogenesis in the murine adrenals. Also in human, bilateral ORX increase serum LH levels 52 . Moreover, it has been shown that human adrenal gland express LH receptor in the adrenal cortex cells in the reticular layer 53 , it was speculated that GnRH analog treatment may reduce adrenal steroidogenesis via suppressing the circulating LH. Currently, ADT is mainly achieved by chemical castration by GnRH analogs.
However, cumulating evidence suggests that long term chemical castration is associated, for example, with higher risk of bone fractures and cardiovascular events compared to ORX 54 . Thus, there has been discussion on whether surgical castration should be favored over the GnRH analog treatment [54] [55] [56] . These data suggesting that high LH level after ORX is activating adrenal steroidogenesis would, however, favor the use of GnRH analogs in the treatment of PCa patients.
The correlation between intratumoral and circulating androgen concentrations indicates a systemic
contribution to intratumoral androgen levels. In addition, in ORX mice, circulating P 4 is also a M A N U S C R I P T
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16 likely precursor for the local androgen production in castration-resistant VCaP tumors. Previous studies have reported P 4 in the circulation in mice after ORX 17, 33 but its origin has not been well established. Some studies suggest that production of P 4 in the tumors is the main source of the circulating P 4 in PCa xenograft bearing ORX mice 22, 57 , whereas the current data indicate a major role for adrenal P 4 production. It is well established that the human AR with the T878A mutation is strongly stimulated by P 4 24 , and there is some evidence to suggest that P 4 may induce AR action under the conditions of high AR expression 2, 58 . As increased levels of AR are present in CRPC tumors 59 , it is possible that also non-classical, low affinity ligands, such as P 4 , can stimulate AR.
Nevertheless, P 4 is only a very weak agonist for the wild-type AR (AR-FL), and based on the present data, i can be concluded that DHT, present at substantial concentrations in castrationresistant VCaP xenografts, is the main driver of intratumoral AR signaling in the ORX and ORX+ADX mice. Notably, P 4 may serve as a substrate for steroid 5α-reductases (SRD5A) in the backdoor pathway of DHT synthesis that bypasses the need of T as an intermediate 60 . VCaP xenografts grown in ORX+ADX mice express SRD5A enzymes, and the intratumoral P 4 and DHT levels are comparable to those in tumors from intact animals. This observation, together with a significant decrease of intratumoral T after ORX, and a further reduction after ADX, support the hypothesis of adrenal P 4 as a precursor for intratumoral DHT synthesis via the backdoor pathway.
Furthermore, the possible contribution of novel androgens, such as the 11-keto-T and 11-keto-DHT 61 , to the growth of VCaP xenografts in ORX+ADX hosts remains to be determined.
In line with clinical data 62 , our previous study confirmed that ORX induces the expression of fulllength AR and its splice variants 28 
